TARELLA, CORRADO
TARELLA, CORRADO
Dipartimento di Scienze della Salute
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
2024 C. Restelli, M. Ruella, L. Paruzzo, C. Tarella, P.G. Pelicci, E. Colombo
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
2023 S. Mazzara, L. Travaini, F. Botta, C. Granata, G. Motta, F. Melle, S. Fiori, V. Tabanelli, A. Vanazzi, S. Ramadan, T. Radice, S. Raimondi, G. Lo Presti, M.E. Ferrari, B.A. Jereczek-Fossa, C. Tarella, F. Ceci, S. Pileri, E. Derenzini
[¹⁸ F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma [$\less$sup$\greater$18$\less$/sup$\greater$F]-{FDG} {PET} radiomic model as prognostic biomarker in diffuse large B-cell lymphoma]
2023 L. Lavinia Travaini, F. Botta, E. Derenzini, G. Lo Presti, M. Esmeralda Ferrari, L. Simona Air(`(o)) Farulla, T. Radice, S. Mazzara, C. Tarella, S. Pileri, S. Raimondi, F. Ceci
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
2022 F.H. Schjesvold, M.-. Dimopoulos, S. Delimpasi, P. Robak, D. Coriu, W. Legiec, L. Pour, I. Spicka, T. Masszi, V. Doronin, J. Minarik, G. Salogub, Y. Alekseeva, A. Lazzaro, V. Maisnar, G. Mikala, L. Rosinol, A.M. Liberati, A. Symeonidis, V. Moody, M. Thuresson, C. Byrne, J. Harmenberg, N.A. Bakker, R. Hajek, M.-. Mateos, P.G. Richardson, P. Sonneveld, F. Schjesvold, A. Nikolayeva, W. Tomczak, L. Pour, I. Spicka, G. Mikala, L. Rosinol, T. Konstantinova, A. Symeonidis, M. Gatt, A. Illes, H. Abdulhaq, M. Dungarwalla, S. Grosicki, R. Hajek, X. Leleu, A. Myasnikov, P.G. Richardson, I. Avivi, D. Deeren, M. Gironella, M.T. Hernandez-Garcia, J. Martinez Lopez, M. Newinger-Porte, P. Ribas, O. Samoilova, E. Voog, M. Arnao-Herraiz, E. Carrillo-Cruz, P. Corradini, J. Dodlapati, M. Granell Gorrochategui, S.-. Huang, M. Jenner, L. Karlin, J.S. Kim, A. Kopacz, N. Medvedeva, C.-. Min, R. Mina, K. Palk, H.-. Shin, S.K. Sohn, J. Tache, A. Anagnostopoulos, J.-. Arguinano, M. Cavo, J. Filicko, M. Garnes, J. Halka, K. Herzog-Tzarfati, N. Ipatova, K. Kim, M.-. Krauth, I. Kryuchkova, M.C. Lazaroiu, M. Luppi, A. Proydakov, A. Rambaldi, M. Rudzianskiene, S.-. Yeh, M.M. Alcala-Pena, A. Alegre Amor, H. Alizadeh, M. Bendandi, G. Brearton, R. Brown, J. Cavet, N. Dally, M. Egyed, J.A. Hernandez-Rivas, A. Kaare, J.-. Karsenti, J. Kloczko, W. Kreisle, J.-. Lee, S. Machherndl-Spandl, S. Manda, I. Moiseev, J. Moreb, Z. Nagy, S. Nair, A. Oriol-Rocafiguera, M. Osswald, P. Otero-Rodriguez, V. Peceliunas, T. Plesner, P. Rey, G. Rossi, D. Stevens, C. Suriu, C. Tarella, A. Verlinden, A. Zannetti
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma
2022 F. Bonfiglio, A. Bruscaggin, F. Guidetti, L. Terzi di Bergamo, M.R. Faderl, V. Spina, A. Condoluci, L. Bonomini, G. Forestieri, R. Koch, D. Piffaretti, K. Pini, M.C. Pirosa, M.G. Cittone, A. Arribas, M. Lucioni, G. Ghilardi, W. Wu, L. Arcaini, M.J. Baptista, G. Bastidas, S. Beà, R. Boldorini, A. Broccoli, M.M. Bühler, V. Canzonieri, L. Cascione, L. Ceriani, S.B. Cogliatti, P. Corradini, E. Derenzini, L. Devizzi, S. Dietrich, A.R. Elia, F. Facchetti, G. Gaidano, J.F. Garcia, B. Gerber, P. Ghia, M. Gomes da Silva, G. Gritti, A. Guidetti, F. Hitz, G.G. Inghirami, M. Ladetto, A. López-Guillermo, E. Lucchini, A. Maiorana, R. Marasca, E. Matutes, V. Meignin, M. Merli, A.A. Moccia, M. Mollejo, C. Montalban, U. Novak, D.G. Oscier, F. Passamonti, F.A. Piazza, S. Pizzolitto, A. Rambaldi, E. Sabattini, G.A. Salles, E. Santambrogio, L. Scarfo, A. Stathis, G. Stussi, J.T. Geyer, G. Tapia, C. Tarella, C. Thieblemont, T. Tousseyn, A. Tucci, G. Vanini, C. Visco, U. Vitolo, R. Walewska, F. Zaja, T. Zenz, P.L. Zinzani, H. Khiabanian, A. Calcinotto, F. Bertoni, G. Bhagat, E. Campo, L. de Leval, S. Dirnhofer, S.A. Pileri, M.A. Piris, A. Traverse-Glehen, A. Tzankov, M. Paulli, M. Ponzoni, L. Mazzucchelli, F. Cavalli, E. Zucca, D. Rossi
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients
2022 E. Derenzini, A. Gueli, A. Risso, R. Bruna, D. Gottardi, A. Cignetti, S. Pileri, E.V. Avvedimento, C. Tarella
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
2022 V. Tabanelli, F. Melle, G. Motta, S. Mazzara, M. Fabbri, C. Agostinelli, A. Calleri, M. Del Corvo, S. Fiori, D. Lorenzini, A. Cesano, A. Chiappella, U. Vitolo, E. Derenzini, G.K. Griffin, S.J. Rodig, A. Vanazzi, E. Sabattini, C. Tarella, M.R. Sapienza, S.A. Pileri
Prognostic impact of baseline immunologic profile in aggressive b-cell non-hodgkin's lymphomas
2021 S. Ramadan, G. Ceparano, A. Cignetti, S. Sammassimo, V. Bagnardi, E. Pagan, D. Gottardi, S. Fiori, R. Passerini, T. Radice, G. Saglio, C. Tarella
Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors : a single-center experience
2021 E. Todisco, F. Gigli, M. Mantiero, S. Sammassimo, R. Pastano, C. Ronchini, G. Parma, M.T. Lapresa, A.P. Iori, F. Bertolini, C. Corsini, G. Gregato, C. Poletti, N. Colombo, C. Tarella
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
2021 S. Cortelazzo, M. Mian, A. Evangelista, L. Devizzi, P. Corradini, M. Magni, M. Ladetto, S. Ferrero, A. Rossi, A.M. Barbui, C. Patti, A. Costa, U. Vitolo, A. Chiappella, F. Benedetti, A.J.M. Ferreri, P. Nicoli, L. Rigacci, C. Castellino, A.M. Gianni, A. Rambaldi, C. Tarella
HHV8-negative effusion-based large B cell lymphoma arising in chronic myeloid leukemia patients under dasatinib treatment : A report of two cases
2021 S. Fiori, E. Todisco, S. Ramadan, F. Gigli, P. Falco, A. Iurlo, C. Rampinelli, G. Croci, S.A. Pileri, C. Tarella
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma
2021 E. Derenzini, V. Tabanelli, S. Sammassimo, S. Mazzara, G. Motta, F. Melle, A. Vanazzi, A. Calleri, S. Fiori, M.C. Finazzi, M.C. Barbanti, S. Ramadan, S. Gandini, R. Pastano, A. Rambaldi, S. Pileri, C. Tarella
Peripheral t‐cell lymphoma, not otherwise specified : Clinical manifestations, diagnosis, and future treatment
2021 S.A. Pileri, V. Tabanelli, S. Fiori, A. Calleri, F. Melle, G. Motta, D. Lorenzini, C. Tarella, E. Derenzini
Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome
2021 R. Clari, C. Tarella, R. Giraudi, M.C. Torazza, E. Gallo, A. Lavacca, F. Fop, A. Mella, C. Dolla, L. Biancone
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma
2021 A. Rossi, S. Orecchioni, P. Falvo, V. Tabanelli, E. Baiardi, C. Agostinelli, F. Melle, G. Motta, A. Calleri, S. Fiori, C. Corsini, B. Casadei, S. Mazzara, U. Vitolo, F. Bertolini, P.L. Zinzani, M. Alcalay, P.G. Pelicci, S. Pileri, C. Tarella, E. Derenzini
Tips and tricks for writing a scientific manuscript
2020 A. Marmotti, G.M. Peretti, L. Mangiavini, L. de Girolamo, C. Tarella, D.E. Bonasia, S. Mattia, A. Tellini, E. Bellato, G. Agati, D. Blonna, F. Castoldi
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial
2020 A. Romano, C. Pavoni, F. Di Raimondo, C. Tarella, S. Viviani, A. Rossi, C. Patti, M. Picardi, M. Cantonetti, G. La Nasa, L. Trentin, S. Bolis, V. Zoli, P. Gavarotti, P. Corradini, M. Cimminiello, C. Schiavotto, G. Parvis, R. Zanotti, G. Gini, A.J.M. Ferreri, P. Viero, S. Chauvie, A. Biggi, A. Massimo Gianni, A. Gallamini, A. Rambaldi
Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis : A rare and life-treating condition
2020 G. Lo Iacono, F. Gigli, L. Gherzi, D. Avenoso, S. Fiori, G. Sedda, C. Tarella, L. Spaggiari
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)
2020 P. Salamone, G. Fuda, F. Casale, G. Marrali, C. Lunetta, C. Caponnetto, L. Mazzini, V. La Bella, J. Mandrioli, I.L. Simone, C. Moglia, A. Calvo, C. Tarella, A. Chio
Efficacy of venetoclax based salvage chemotherapy followed by “Minimal Residual Disease driven”-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia
2020 E. Todisco, F. Gigli, S. Sammassimo, C. Camisaschi, P. Mancuso, C. Ronchini, S. Ramadan, F. Bertolini, R. Pastano, C. Tarella